February 27, 2019
Acrux’s ACX-362E therapeutically relevant for patients with CDI
Acurx Pharmaceuticals’ recently completed test showed that at well-tolerated doses ACX-362E reaches concentrations in the colon that are projected to be therapeutically relevant for patients with Clostridioides difficile infection (CDI).